close

Agreements

1 2 3 221
Number of results: 4419

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2017-10-03 Merck KGaA (Germany) new production line at the manufacturing site of Bari construction of new premises Construction of new premises
2017-10-03 Lonza (Switzerland) Shire (UK - USA) clinical-stage mammalian manufacturing site  in Hayward (USA - CA) plant acquisition Technology - Services Plant acquisition
2017-09-29 TG Therapeutics (USA - NY) Fast Forward (USA - NY) TGR-1202 (umbralisib) progressive multiple sclerosi clinical research Neurodegenerative diseases Clinical research agreement
2017-09-20 Enterome Bioscience (France) research laboratories in Genopole opening of new premises Autoimmune diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology Opening of new premises
2017-09-18 Immunocore (UK) Bill and Melinda Gates Foundation (USA) ImmTAV (Immune mobilising monoclonal TCRs Against Virus) and ImmTAB (Immune mobilising monoclonal TCRs Against Bacteria) therapeutics HIV infection, tuberculosis development Infectious diseases Development agreement
2017-09-17 Merck&Co (USA - NJ) Zymeworks (Canada) bispecific antibody therapeutic candidates generated through use of the Azymetric™ platform development - licensing - commercialisation undisclosed Milestone
2017-09-14 Daiichi Sankyo (Japan) The University of Texas MD Anderson Cancer Center (USA - TX) quizartinib, DS-3032,  DS-3201, and PLX51107 acute myeloid leukemia (AML) development Cancer - Oncology Development agreement
2017-09-13 Onxeo (France) Monopar Therapeutics (USA - IL) Validive® (clonidine mucoadhesive buccal tablet) severe oral mucositis induced by radiotherapy or chemotherapy in patients suffering from head and neck cancer licensing Cancer - Oncology Licensing agreement
2017-09-12 Alexion Pharmaceuticals (USA - CT) restructuring Rare diseases - Genetic diseases Restructuring
2017-09-12 TiGenix (Belgium) head of medical department (US), director nomination Autoimmune diseases – Inflammatory diseases - Cardiovascular diseases Nomination
2017-09-11 Teva Pharmaceutical (Israel) president and chief executive officer nomination Nomination
2017-09-11 Allergy Therapeutics (UK) clinical director, head of clinical science, senior pharmaceutical physician nomination Allergic diseases Nomination
2017-09-07 Adaptimmune (UK) GSK (UK) NY-ESO SPEAR T-cell therapy program including GSK3377794 synovial sarcoma, myxoid round cell liposarcoma licensing Cancer - Oncology Exercise of an option agreement
2017-09-07 Cell Therapy Catapult (UK) TrakCel (UK) needle-to-needle supply chain management platform collaboration Technology - Services Collaboration agreement
2017-09-07 Eli Lilly (USA - IN) restructuring Restructuring
2017-09-07 Abivax (France) Evotec (Germany) small molecules for the treatment of multiple serious viral infectious diseases viral infectious diseases development Infectious diseases Development agreement
2017-09-06 Pharmaxis (Australia) Synairgen (UK) selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) idiopathic pulmonary fibrosis R&D - research Lung diseases - Respiratory diseases - Rare diseases R&D agreement
2017-09-05 Boehringer Ingelheim (Germany) Inventiva (France) new medicines for the treatment of idiopathic pulmonary fibrosis idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases research - R&D - licensing Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases Exercise of an option agreement
2017-09-05 Portola Pharmaceuticals (USA - CA) Lonza (Switzerland) AndexXa®(US)/ IndexXa™ (EU) production - manufacturing Production agreement
2017-09-05 TiGenix (Belgium) manufacturing facility in Madrid validation of a production plant Autoimmune diseases - Inflammatory diseases Validation of a production plant